BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

852 related articles for article (PubMed ID: 20571232)

  • 1. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer.
    Fehm T; Jäger W; Krämer S; Sohn C; Solomayer E; Wallwiener D; Gebauer G
    Anticancer Res; 2004; 24(3b):1987-92. PubMed ID: 15274389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.
    Ebeling FC; Schmitt UM; Untch M; Nagel D; Fateh-Moghadam A; Stieber P; Seidel D
    Anticancer Res; 1999; 19(4A):2545-50. PubMed ID: 10470192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between preoperative serum markers CA 15-3 and CEA and relapse of the disease in elderly (>65 years) women with breast cancer.
    Lumachi F; Basso SM; Bonamini M; Marzano B; Milan E; Waclaw BU; Chiara GB
    Anticancer Res; 2010 Jun; 30(6):2331-4. PubMed ID: 20651388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.
    Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM
    Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.
    Molina R; Filella X; Alicarte J; Zanon G; Pahisa J; Munoz M; Farrus B; Ballesta AM
    Anticancer Res; 2003; 23(2A):1035-41. PubMed ID: 12820344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery.
    Nakamura T; Kimura T; Umehara Y; Suzuki K; Okamoto K; Okumura T; Morizumi S; Kawabata T
    Surg Today; 2005; 35(1):19-21. PubMed ID: 15622458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
    Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
    Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
    Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
    Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence in breast cancer. Analysis with frailty model.
    Gohari MR; Mahmoudi M; Mohammed K; Pasha E; Khodabakhshi R
    Saudi Med J; 2006 Aug; 27(8):1187-93. PubMed ID: 16883450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3.
    Lumachi F; Brandes AA; Boccagni P; Polistina F; Favia G; D'Amico DF
    Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
    Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
    Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
    Hu XC; Day W; Jones B; Loo WT; Chow LW
    Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
    Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors.
    Lumachi F; Brandes AA; Ermani M; Bruno G; Boccagni P
    Anticancer Res; 2000; 20(6C):4751-5. PubMed ID: 11205212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of pre-operative serum CA 15.3 levels in breast cancer.
    Martín A; Corte MD; Alvarez AM; Rodriguez JC; Andicoechea A; Bongera M; Junquera S; Pidal D; Allende T; Muñiz JL; Vizoso F
    Anticancer Res; 2006; 26(5B):3965-71. PubMed ID: 17094428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.